Cumberland director granted 1,800 shares of stock

Galante Joseph C reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Galante Joseph C reported acquisition or exercise transactions in this Form 4 filing.

Cumberland Pharmaceuticals director Joseph C. Galante received a grant of 1,800 shares of Common Stock at $2.80 per share. This award increases his directly held stake to 63,656 shares. The transaction is classified as a grant or award, not an open-market purchase.

Insider Trade Summary

Grant/Award: 1,800 shares

Grant/Award 1 txn

Insider Galante Joseph C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,800	$2.80	$5K

Holdings After Transaction: Common Stock — 63,656 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Joseph C. Galante report at Cumberland Pharmaceuticals (CPIX)?

Joseph C. Galante reported receiving a grant of 1,800 shares of Cumberland Pharmaceuticals Common Stock at $2.80 per share. The Form 4 classifies this as a grant or award acquisition, rather than an open-market purchase of shares.

How many Cumberland Pharmaceuticals (CPIX) shares does Joseph C. Galante hold after this grant?

Following the 1,800-share grant, Joseph C. Galante directly holds 63,656 shares of Cumberland Pharmaceuticals Common Stock. This total reflects his position after the reported non-derivative award transaction on the Form 4 filing.

Was the Cumberland Pharmaceuticals (CPIX) insider transaction a purchase or an award?

The transaction was an award, not a market purchase. The Form 4 lists it under code A, described as a grant, award, or other acquisition, indicating compensation-related stock rather than shares bought on the open market.

What price was used for Joseph C. Galante’s Cumberland Pharmaceuticals (CPIX) stock grant?

The reported grant to Joseph C. Galante used a reference price of $2.80 per share for 1,800 shares of Common Stock. This value appears in the Form 4 as the transaction price per share for the non-derivative stock award.

Does the Form 4 for Cumberland Pharmaceuticals (CPIX) show any stock sales by Joseph C. Galante?

The Form 4 does not report any sales. It shows one acquisition transaction coded A for a 1,800-share grant of Common Stock, with no entries indicating dispositions, sales, tax withholdings, or derivative exercises in this filing.

Is Joseph C. Galante’s ownership in Cumberland Pharmaceuticals (CPIX) direct or indirect after this transaction?

His ownership is reported as direct. The Form 4 marks the nature of ownership as direct, with 63,656 Common Stock shares held directly by Joseph C. Galante following the 1,800-share grant transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/20/2026 - 05:23 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Galante Joseph C

(Last)

(First)

(Middle)

1600 WEST END AVENUE

SUITE 1300

(Street)

NASHVILLE

TENNESSEE

37203

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/18/2026		A		1,800	A	$2.8	63,656	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Remarks:

	Joseph C. Galante /s/ John Hamm as attorney -in-fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR